BIO-IT & DIGITAL HEALTH

Company directory of Germany’s data-driven life sciences
Summary

Health – Made in Germany, an initiative of the German Federal Ministry for Economic Affairs and Energy, is publishing this directory of Bio-IT and digital health companies in Germany. The initiative is the first place partners from abroad should look to find out how they can tap into and benefit from Germany’s expertise in the field of Bio-IT and digital health.

Health – Made in Germany holds the key to accessing the experience of Germany’s medical biotech and digital health companies. It provides information, links partners, and paves the way for applying German know-how to serving people around the globe. In addition to helping locate the right partners in Germany, the initiative provides support when it comes to getting cooperative ventures up and running as well.

Another feature of Health – Made in Germany is its English-language website www.health-made-in-germany.com. The site features news, information and the latest on exhibitions, trade missions, and what is going on in German healthcare. Taking the initiative to find out more from Health – Made in Germany is as easy as clicking a mouse. Please get in touch.

Germany Trade & Invest (GTAI) is implementing the initiative as commissioned by Germany’s Federal Ministry for Economic Affairs and Energy. GTAI is the economic development agency of the Federal Republic of Germany.
Content

2 SUMMARY

INTRODUCTION

4 Smart solutions for data-driven life sciences

4 Innovations in Bio-IT
6 Digital health boom
6 Young ventures
7 Government initiatives

INDUSTRY ASSOCIATIONS

8 Industry associations in detail

MATRIX

12 Company and technology overview

COMPANY PROFILES

16 Companies in detail

51 IMPRINT
INTRODUCTION

Smart solutions for data-driven life sciences

Big data is everywhere, and the digital change is permeating the life sciences and health sector. The fields of Bio-IT and digital health aim at the creation of information that will be useful to researchers, doctors and even patients. German companies are developing top-notch technology in both fields – a portrait of a smart landscape.

With a seemingly endless stream of biological data being generated across a range of sectors, the need for data analysis and interpretation – a highly dynamic field at the crossroads of biology, statistics, and computer science – is greater than ever.

Today, the generation of data in biosciences and medicine has become relatively easy and less costly, and by far the most challenging task is to make sense of the wealth of available data. Analyzing vast quantities of information and presenting it in a clear manner to decision makers – be they scientists, doctors, or even patients – is considered as key to new and promising business models.

A remarkably high number of companies in Germany is specialized in developing smart solutions for bioinformatics and digital healthcare. Their core tasks include clarification of genomics, proteomics and metabolomics data analyses, the provision of decision support tools for health professionals in diagnostics and therapy, the development and maintenance of archiving systems and the provision of suitable Bio-IT infrastructure.

This guide will help you gain an understanding of the powerful solutions that German companies in the fields of Bio-IT and digital health have to offer in the analysis and organization of biological data. Due to the size of the German Bio-IT and digital healthcare providers’ market, this guide cannot be entirely comprehensive. However, it aims to give a thorough overview of the broad spectrum of their products and services.

Innovations in Bio-IT

High-throughput molecular technologies such as genome sequencing or high-definition-imaging have become routine applications in life sciences
research around the globe. The so-called ‘omics’-technologies, such as genomics, proteomics and metabolomics, produce mountains of digital data that are the essential raw material of biomedical research. Analyzing these data and extracting relevant information has become a core expertise for a great many bioinformatics firms in Germany.

Searching through mountains of biological data
In this guide, companies specialized in data analysis comprise a separate category of their own. In all, a striking number of young firms have found a niche in the B2B market in particular in recent years.

A majority of these are specialized in the field of genomics, namely the analysis of information derived from DNA or RNA sequencing. Next-generation sequencing (NGS) has become the dominant data source, and many companies have developed software and hardware solutions for analyzing the constant stream of data that is supplied by high-throughput sequencing machines.

Protein and proteome analysis is another field that generates vast quantities of data and which demands superior expertise in data mining and data interpretation. The results from mass spectrometry experiments and other protein characterization techniques are fundamental to biomedical research.

The field of systems biology, which aims at the computational simulation and mathematical modeling of complex biological phenomena, for example the nervous system, stem cells or even the brain, represents another level of complexity altogether.

Tools for clinical research and drug developers
Computer-based analysis of experimental data generated by high-throughput technologies not only enables current basic research in the life sciences, but by helping the pharma industry and biotech companies to identify new drug targets and reliable biomarkers, it is also transforming central principles of clinical research.

The identification of genetic variants and their annotation with other health information has become a key procedure in the era of precision medicine. German Bio-IT companies have developed powerful tools and solutions for creating high value out of biological data for clinical research and drug development – be it in the academic sector, in biotech, or the pharma industry.

Others provide the IT solutions that are required for performing clinical studies, ranging from study design, patient recruitment and statistical analyses of outcomes. Storing information and archiving digital images and other health data is also an important aspect covered by such companies.

Providing decision support
The emerging field of biomedical informatics aims at the integration of knowledge on patient history, medical history, family history and genomic background, which taken together can provide valuable clinical insights. Thus, specialized IT firms provide a computational decision support structure that helps doctors to either select a drug combination that perfectly matches the patient’s genomic profile, or to gain real-world data on the therapeutic response of a treatment.

Smart path: Bioinformatics and digital health applications
German Bio-IT and digital health companies listed in this guide were identified and categorized by their fields of activity

<table>
<thead>
<tr>
<th>Data analysis</th>
<th>Clinical research and translational informatics</th>
<th>Clinical decision support</th>
<th>Software</th>
</tr>
</thead>
<tbody>
<tr>
<td>genomics</td>
<td>development of diagnostics</td>
<td>for healthcare professionals</td>
<td>organization/documentation</td>
</tr>
<tr>
<td>proteomics</td>
<td>development of therapeutics</td>
<td>for clinical laboratories</td>
<td>for individuals</td>
</tr>
<tr>
<td>systems biology</td>
<td></td>
<td></td>
<td>for medical devices</td>
</tr>
</tbody>
</table>
From an economic perspective, digital health is a fast-developing market with estimated annual growth of 21% by 2020, by which time the digital health market is expected to reach US$233 billion. This growth means new opportunities for pharma and life sciences companies and, as a result, they are expanding activities in bioinformatics and digital health technologies.

The largest driver of this digital transition is the mobile health market. As a consequence of short development cycles and the earlier ready-to-market-status of software solutions, startups at the interface of IT and health are also of interest for investors from outside the traditional life sciences investor community.

Patient engagement

Worldwide, there are more than 170,000 mobile healthcare apps as well as countless websites and online portals dedicated to every imaginable aspect of sickness and health. This demonstrates that patients and consumers are open to this kind of technological innovation. This openness also corresponds with a cultural change – people are now more confident in the active shaping of their own way of living.

The propagation of such services is largely driven by ordinary people and less by institutionalized healthcare stakeholders. For instance, a report by the University Medical Clinic Freiburg showed that patients in Germany want to be more involved in decision-making processes during preventive medical care, as well as during disease management.

Until now, pharmaceutical and biotech companies were utilizing digital tools predominantly for sales and marketing purposes. The new concept of ‘service beyond the pill’ aims to create value by embedding products into an integrated overall offer, with the objective of improving patient outcomes, and of course to provide a tangible competitive advantage.

Big Pharma teams up with IT giants

Examples of this integrated approach include tele-health services, wellness programs, and improved chronic disease management with sophisticated smartphone apps and applicators. Most pharma giants have entered collaboration schemes with well-established IT companies.

The key issues in most of these partnerships are big data management and interconnectivity. The advent of easy-to-use mobile health sensors promises more straightforward disease management, as well as more effective clinical trials. Data sharing and connected health have become buzzwords in recent years.

Young ventures

In Germany, this development has served as the backbone for the growth of a lively startup community. Today, the majority of startups based in Germany offer solutions for medical everyday life, diagnosis, and patient therapy. In addition, new IT-based serv-
ices such as video doctor consultancies or medical records for smartphones are entering the stage, as well as coaching apps or therapeutic apps that offer additional support to patients.

Many of these young companies have their roots in academia. To guide their precious products to market, numerous so-called incubators and accelerators have sprung up all over the country. Here, newcomers work under the patronage and with the support of established companies.

Most of these are venture capital enterprises and larger pharma groups, but they can also include IT and insurance companies hoping to benefit from clever ideas nurtured in their specialist sphere of influence.

Mecca for digital health startups
Berlin is well known for its ecosystem of IT and business networks. It thus comes as no surprise that a majority of healthcare-IT-related accelerator programs for startups are based in the German capital. Major pharma companies as well as independent accelerators are further promoting the digital health startup sector.

Government initiatives
As both the virtual doctor-patient-relationship and the use of medical apps for preventive medical care necessitate great confidence in the protection and safety of personal health data, the German healthcare community is establishing a nationwide, technically mature telematics infrastructure for connecting insurants, doctors, hospitals and health insurance companies.

The telematics platform is based on electronic health cards for each insured citizen. Medical data can only be unlocked when both the examining physician and the patient provide their respective key codes.

Telematics infrastructure
In 2015, the German government moved to speed up the implementation of this system with the approval of the so-called eHealth Act. Beginning in mid-2016, the Act lays down fixed dates for the introduction of a variety of subsystems. By 2018, every doctor’s office as well as hospitals nationwide should be connected to the telematics infrastructure.

More information:
www.health-made-in-germany.com
INDUSTRY ASSOCIATIONS

Industry associations in detail
BIO Deutschland e. V.

Contact: Dr. Claudia Englbrecht
Am Weidendamm 1a · 10117 Berlin
Tel.: +49-30-72625-130 · Fax: +49-30-72625-138
Mail: info@biodeutschland.org · Web: www.biodeutschland.org

The Biotechnologie-Industrie-Organisation Deutschland (BIO Deutschland) is an independent organization for innovative biotechnology companies in Germany. At its offices in Berlin, the association is developing and supporting an innovative industry based on modern life sciences. Founded in October 2004, BIO Deutschland currently has more than 320 member companies and several supporting members and sector partners. To support its members BIO Deutschland engages in a broad range of activities, including lobbying, public relations, and offering business development opportunities. Using a wide range of political initiatives, BIO Deutschland lobbies for improvements to legal parameters for innovative small and medium-sized enterprises. The association is also very active in a broad range of events with the aim of providing biotechnology with a platform for discussion and interaction. The German Biotechnology Days, a yearly national forum for biotechnology with more than 800 attendees, is organized jointly by BIO Deutschland, the Council of the German Bioregions and regional hosts.

BIO Deutschland is governed by a managing board of CEOs, CFOs and Managing Directors of companies that represent the German biotech sector. This committee comprehensively represents the various fields in the sector.

BIO Deutschland’s member companies and their experts are organized in working groups that deal with a variety of subjects relevant to the biotech sector and small and medium sized companies. The groups meet regularly to discuss current developments, to draft position papers, to exchange ideas and to network. A total of twelve working groups and one network for communication and PR are active in the association.

Working groups for the following topics are currently installed:

- Big data and Bio-IT
- Diagnostics
- Finance and Taxation
- German-US Cooperation
- Licenses and Technical Contracts
- Regulatory Affairs
- Entrepreneurship, Innovation and Jobs
- Human Resources
- Industrial Bio-Economy
- Industrial Cell Technology
- Health Policy and Technology Transfer

BIO Deutschland is also partner of several other associations such as BVMW, The German Association for Small and Medium-sized Businesses, Biosingapore, bts – Biotechnology Student Initiative, BVIZ – German Association of Innovation, Technology and Business Incubation Centers, EAPB – European Association of Pharma Biotechnology, EUCOPE – European Confederation of Pharmaceutical Entrepreneurs, German-Sino Healthcare Group, ICLS- International Council for the Life Sciences and VBIO – German Life Sciences Association. Additionally BIO Deutschland administrates the head office of the Council of German Bioregions.

BIO Deutschland is Germany’s biotechnology sector representative at the European association, EuropaBio, in Brussels. BIO Deutschland also collaborates closely with other biotech organizations in Europe and the USA in order to lobby for the interests of the sector in an internationally coordinated way. It is a founding member of the International Council of Biotechnology Associations (ICBA) and (affiliated) member of the Biotechnology Innovation Organization (BIO) USA.
For a culture of innovation
Innovation is at the bottom of it all. Innovation has not only set the basis for the industrial development in Germany, it has also enabled for Germany to stay at the very top so far in the increasing global competition.

Scientific publications and patent registration are often taken as the indicator of the innovative power of a society. But this is not the whole truth. Innovation requires more than the development of a new industrial design, and it means more than research results and even more than a brilliant idea. Innovation implies that this idea or result is brought to real life, that it finds an expression in new products or services that meet a market demand.

A more positive entrepreneurial culture
Germany has excellent academic research, yet it is not really known as a country with a lively founding scene. A report states that education in schools with regards to founding needs to be improved, societal values and standards need to be adjusted for a more positive entrepreneurial culture, and labor supply needs to be increased for new and growing businesses.

In short: Motivating more people to set out on the big adventure of founding a new business is not so much a question of the financial and institutional framework, it is a question of culture and societal values. While in some other countries the founding of a business is seen as a chance for success, for growth and in any case a valuable experience, in Germany founding is regarded rather suspiciously – it contradicts widely accepted values such as security, firm structures, and a potential failure is regarded as a stain in one's CV rather than an interesting feature.

Visibility for founders
The challenges have been identified, though, and countermeasures are being taken. A large number of initiatives are dedicated to technology transfer; universities and other research institutions have established technology transfer agencies that scout academic research groups for marketable technologies. Competitions and funding programs such as the GO Bio Initiative of the German Federal Ministry of Research and Education or the Science4Life competition provide financing, advice and visibility for founders, and their number is increasing. Last year, for example, the ACHHEMA Gründerpreis was awarded for the first time to innovative entrepreneurs active in the fields of energy, industrial biotechnology and analytics. The nine finalists had the unique opportunity to present their concepts to industry experts from all over the world. This is an invaluable chance as many founders report that one of the hardest tasks is to identify and approach the right people in large companies in order to position themselves as potential suppliers, customers or development partners.

Our mission: innovation
From its beginning, the VBU Vereinigung Deutscher Biotechnologie-Unternehmen set out to enable technology transfer and facilitate networking between academic research and industry. With a special focus on small and medium sized enterprises, the VBU offers advice and organizes events tailored to give information and support to start-ups during their growth and expansion phase, both nationally and internationally. Being a part of DECHEMA, the large network for chemical process technology and biotechnology, it is the home for people active in research whether in universities, independent research institutions, start-ups or “big businesses”. The activities of VBU supplement the approximately 120 topical working groups within DECHEMA, around 20 of them covering biotechnology from Omics and Cell Culture to Bio-processing and Single-Use Technologies. The mission of VBU is as up-to-date as it was 20 years ago, and as long as there are people with brilliant ideas, it will always be up-to-date.

Association of German Biotech Companies (VBU)
in DECHEMA e.V.
Contact: Dr. Andreas Scriba
Theodor-Heuss-Allee 25 · 60486 Frankfurt am Main
Tel.: +49-69-7564-124 · Fax: +49-69-7564-169
Mail: scriba@dechema.de · Web: www.v-b-u.org · www.dechema.de

Association of German Biotech Companies (VBU) in DECHEMA e.V.

Research and Education or the Science4Life competition provide financing, advice and visibility for founders, and their number is increasing. Last year, for example, the ACHHEMA Gründerpreis was awarded for the first time to innovative entrepreneurs active in the fields of energy, industrial biotechnology and analytics. The nine finalists had the unique opportunity to present their concepts to industry experts from all over the world. This is an invaluable chance as many founders report that one of the hardest tasks is to identify and approach the right people in large companies in order to position themselves as potential suppliers, customers or development partners.

Our mission: innovation
From its beginning, the VBU Vereinigung Deutscher Biotechnologie-Unternehmen set out to enable technology transfer and facilitate networking between academic research and industry. With a special focus on small and medium sized enterprises, the VBU offers advice and organizes events tailored to give information and support to start-ups during their growth and expansion phase, both nationally and internationally. Being a part of DECHEMA, the large network for chemical process technology and biotechnology, it is the home for people active in research whether in universities, independent research institutions, start-ups or “big businesses”. The activities of VBU supplement the approximately 120 topical working groups within DECHEMA, around 20 of them covering biotechnology from Omics and Cell Culture to Bio-processing and Single-Use Technologies. The mission of VBU is as up-to-date as it was 20 years ago, and as long as there are people with brilliant ideas, it will always be up-to-date.
The German Association of Biotechnology Industries (DIB) and its national, European and global networks are the voice and leading industry representation for the innovative and dynamic biotechnology industry that operates in and from Germany.

DIB is the biotechnology division of the Association of the German Chemical Industry Association (VCI). DIB is supported by 10 member associations and sector groups of the VCI:

- German Crop Protection, Pest Control and Fertilizer Association
- German Diagnostic Manufacturers Association
- German Cosmetics and Detergents Association
- VCI Sector Group Food Additives
- German Association of Research-Based Pharmaceutical Companies
- German Association for Food Law and Food Sciences
- German Medical Technology Association
- Association of the German Pharmaceutical Industry
- German Animal Health Association
- Association of the German Chemical Industry Association

Member companies and the above listed industry associations and sector groups are members of DIB. They constitute all in all about 95 % of the biotechnology business operating in and from Germany. This includes many different industry sectors such as polymers, plastics, fine and specialty chemicals, crop protection, plant breeding, enzymes, pharmaceuticals, diagnostics, animal health products, personal care products, detergents, animal feeds, foodstuffs, renewables and derived products. DIB is one of the largest biotechnology industry representations worldwide.

Role of DIB

DIB’s mission is to advocate national, EU and international policies and legislation that uphold a natural science and risk-based approach, foster innovation, operate in a predictable and proportionate way, enable the industry to perform efficiently, protect intellectual property and reward the introduction of new technologies and practices.

- DIB contributes to the creation of internationally competitive framework conditions for use of biotechnology in research, development, production and products.
- DIB represents the political-economic interests of companies that use biotechnology in order to strengthen sustainable growth and the international competitiveness of biotechnology in Germany.
- DIB represents the interests of their members vis-à-vis high-level representatives of legislative bodies, political decision-makers, regulatory authorities, public administration, media and the general public, both nationally and internationally.
- DIB contributes to further strengthening Germany as an industry location.

DIB is a member of the European biotechnology association EuropaBio, member of the board of EuropaBio and currently chairs the National Association Council of EuropaBio.
Company and technology overview

The table below gives an overview of the listed companies and their field of activity. Services and technologies are marked with a circle.

<table>
<thead>
<tr>
<th>Company</th>
<th>Genomics</th>
<th>Proteomics</th>
<th>Systems biology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alacris Theranostics GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alere Technologies Jena GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>apoplex medical technologies GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASANUS Medizintechnik GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATGbiosynthetics GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATLAS Biolabs GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>biologis Genetic Information Management GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BioMath GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biomax Informatics AG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BodyTel GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CeGaT GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cellasys GmbH - R&amp;D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Centogene AG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHILI GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Computomics GmbH &amp; Co. KG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cortex Biophysik GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cunesoft GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Curefab Technologies GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DECODON GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Oestreich + Partner GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Vetter Medizintechnik</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ecSeq GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EvoCare Telemedizin GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GenXPro GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HASOMED GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HealthTwist GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L.E.M. GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMGM Laboratories GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>infoteam Software AG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical research and translational informatics</td>
<td>Clinical decision support</td>
<td>Software</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>--------------------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>Development of diagnostics</td>
<td>Development of therapeutics</td>
<td>for healthcare professionals</td>
<td>for clinical laboratories</td>
</tr>
<tr>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
<tr>
<td>Company</td>
<td>Genomics</td>
<td>Proteomics</td>
<td>Systems biology</td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>----------</td>
<td>------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Insilico Biotechnology AG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JPT Peptide Technologies GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kapelan Bio-Imaging GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lead Discovery Center GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipotype GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOGOPHARM GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>med3D GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEDEORA GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEIERHOFER AG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolomic Discoveries GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>micro-biolytics GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>microDimensions GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MicroDiscovery GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Molecular Health GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEXUS AG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>nova motum® Services &amp; Consulting GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OakLabs GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OmicScouts GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPASCA GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmainformatic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polyquant GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preventicus GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protagen AG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proteome Factory AG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QIAGEN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QuoMedic GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Riboco GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ameda GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scopis GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Siemens Healthineers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sonormed GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>StarSEQ GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systasy Bioscience GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tembit Software GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transinsight GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VISUS Technology Transfer GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitaphone GmbH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zentrum für Humangenetik und Laboratoriumsdiagnostik</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical research and translational informatics</td>
<td>Clinical decision support</td>
<td>Software</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>--------------------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>Development of diagnostics</td>
<td>Development of therapeutics</td>
<td>for healthcare professionals</td>
<td>for clinical laboratories</td>
</tr>
<tr>
<td><img src="image1" alt="Symbol" /></td>
<td><img src="image2" alt="Symbol" /></td>
<td><img src="image3" alt="Symbol" /></td>
<td><img src="image4" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image7" alt="Symbol" /></td>
<td><img src="image8" alt="Symbol" /></td>
<td><img src="image9" alt="Symbol" /></td>
<td><img src="image10" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image14" alt="Symbol" /></td>
<td><img src="image15" alt="Symbol" /></td>
<td><img src="image16" alt="Symbol" /></td>
<td><img src="image17" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image21" alt="Symbol" /></td>
<td><img src="image22" alt="Symbol" /></td>
<td><img src="image23" alt="Symbol" /></td>
<td><img src="image24" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image28" alt="Symbol" /></td>
<td><img src="image29" alt="Symbol" /></td>
<td><img src="image30" alt="Symbol" /></td>
<td><img src="image31" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image35" alt="Symbol" /></td>
<td><img src="image36" alt="Symbol" /></td>
<td><img src="image37" alt="Symbol" /></td>
<td><img src="image38" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image42" alt="Symbol" /></td>
<td><img src="image43" alt="Symbol" /></td>
<td><img src="image44" alt="Symbol" /></td>
<td><img src="image45" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image49" alt="Symbol" /></td>
<td><img src="image50" alt="Symbol" /></td>
<td><img src="image51" alt="Symbol" /></td>
<td><img src="image52" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image56" alt="Symbol" /></td>
<td><img src="image57" alt="Symbol" /></td>
<td><img src="image58" alt="Symbol" /></td>
<td><img src="image59" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image63" alt="Symbol" /></td>
<td><img src="image64" alt="Symbol" /></td>
<td><img src="image65" alt="Symbol" /></td>
<td><img src="image66" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image70" alt="Symbol" /></td>
<td><img src="image71" alt="Symbol" /></td>
<td><img src="image72" alt="Symbol" /></td>
<td><img src="image73" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image77" alt="Symbol" /></td>
<td><img src="image78" alt="Symbol" /></td>
<td><img src="image79" alt="Symbol" /></td>
<td><img src="image80" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image84" alt="Symbol" /></td>
<td><img src="image85" alt="Symbol" /></td>
<td><img src="image86" alt="Symbol" /></td>
<td><img src="image87" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image91" alt="Symbol" /></td>
<td><img src="image92" alt="Symbol" /></td>
<td><img src="image93" alt="Symbol" /></td>
<td><img src="image94" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image98" alt="Symbol" /></td>
<td><img src="image99" alt="Symbol" /></td>
<td><img src="image100" alt="Symbol" /></td>
<td><img src="image101" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image105" alt="Symbol" /></td>
<td><img src="image106" alt="Symbol" /></td>
<td><img src="image107" alt="Symbol" /></td>
<td><img src="image108" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image112" alt="Symbol" /></td>
<td><img src="image113" alt="Symbol" /></td>
<td><img src="image114" alt="Symbol" /></td>
<td><img src="image115" alt="Symbol" /></td>
</tr>
<tr>
<td><img src="image119" alt="Symbol" /></td>
<td><img src="image120" alt="Symbol" /></td>
<td><img src="image121" alt="Symbol" /></td>
<td><img src="image122" alt="Symbol" /></td>
</tr>
</tbody>
</table>
COMPANY PROFILES

Companies in detail
Alacris Theranostics GmbH
Fabeckstr. 60-62 · 14195 Berlin
Tel.: +49-30-8431-225-0 · Fax: +49-30-8431-225-40
Mail: info@alacris.de · Web: www.alacris.de
Founded: 2008 · Employees: 20

Alacris is a Berlin-based company with the mission to transform personalized medicine and targeted drug discovery and development through its unique predictive modeling system ModCell™. Rather than testing novel therapeutic strategies on actual patients, responses to any desired therapeutic scenario are simulated using virtual patient technology (ModCell™), with the ultimate goal of targeting the right patient or patient population. With a focus on cancer, the technology is not only helping to improve treatment outcomes but is also set to impact the drug development pipeline, reducing costs and time to approval.

Our approach represents a completely new solution for both personalized treatment of cancer patients and targeted drug development and approval. ModCell™ predictions are based on simulating drug action within a computer generated model of the highly complex network of biological processes acting within individual tumors. Data generated by in-depth omics analysis of individual tumors are used as a basis for individualized treatment prediction and ‘virtual clinical trials’.

---

Alere Technologies Jena GmbH
Loebsteder Str. 103–105 · 07749 Jena
Tel.: +49-3641-3111-0 · Fax: +49-3641-3111-120
Mail: cct.home@clondiag.com · Web: www.alere-technologies.com
Founded: 1998 · Employees: 400

Alere Technologies GmbH is developing novel point of care diagnostic platforms that move diagnostic testing from the laboratory to the patient. We are committed to establish a testing platform that provides equivalent if not better performance at the point of care if compared to a laboratory test.

In addition, we provide unique microarray-based platforms enabling the development of powerful and competitive multiparameter tests for professional lab diagnostics. Our open platform systems ArrayTube™ and ArrayStrip™ are designed for the development of multiparameter tests for professional lab diagnostics. They allow the efficient conversion of immunological and nucleic acids tests from established formats like ELISA plates or filter membrane strips into a miniaturized array-based format. Thus, previously time consuming and costly tests become simple and affordable.

Based on these platforms, we provide several kits, customized arrays and services for applications in epidemiology, hygiene management, veterinary medicine and others.
The company focuses its activities on the development of applications for the prevention of stroke caused by atrial fibrillation by an improved detection of paroxysmal atrial fibrillation. Several applications are already in use at medical practices and clinics, especially stroke units. The core of the products SRAdoc/SRA24 and SRAclinic is a fully automated detection of atrial fibrillation episodes and the identification of patients with an increased risk for paroxysmal atrial fibrillation with the help of a mathematical algorithm.

The superiority of this method has been proven by clinical studies. The applications are web based and are easy and reliably integrated into each practice or clinic without any major effort.

**ASANUS Medizintechnik GmbH**

take off Gewerbepark 2 · 78579 Neuhausen ob Eck

Tel.: +49-7467-9474-0 · Fax: +49-7467-9474-50

Mail: info@asanus.de · Web: www.asanus.de

Founded: 1998 · Employees: 50

ASANUS Medizintechnik GmbH has developed a mature BarCon Software for tracking surgical instruments, medical material supply and its logistics for hospitals and surgery centers. On top of that, due to further development of the ARIS RFID Chip technology ASANUS Medizintechnik GmbH offers a high innovative tool for individual monitoring of medical products and devices with a very high automation potential.

The company ASANUS Medizintechnik GmbH develops and offers complete tracking software and information technology solutions including RFID Chip tracking. ASANUS is operating in the field of health care and pharmaceutical production.

In accordance with tradition and high-tech-innovations, ASANUS creates your ideal platform for economically reasonable solutions in the operational working environment in hospital.

In addition, it enables you a networked operation according to modern industrial standard 4.0.
The combination of EvoMAG genomics, proprietary molecular database and the lab platform PepID are ATG’s epitope discovery technologies. At ATG a bio-peptide library technology is used for the identification of epitopes concomitant with the assessment of its value for diagnostics and therapeutics. Especially comparative and subtractive genomics of interrelated pathogens in comparison with non-pathogenic species genomes are highly valuable tools for the reduction of molecular complexity and to increase informational relevance. Thus the biodiversity of pathogens by reduction of gene and epitope redundancy especially also repetitive peptide pattern can be eliminated.

This is combined with protein structures based sub-sequence antibody accessibility and exploration of disordered regions. We are using this system to unravel immunologically relevant epitopes or minimal molecular-immune function for chimeric vaccine development e.g. for Mycoplasma spec.

The TANCHOR expression system was designed for protein membrane translocation and its robust display on the surface of mammalian cells.

---

**ATG:biosynthetics GmbH**

Weberstr. 40  ·  79249 Merzhausen  
Tel.: +49-761-8889-424  ·  Fax: +49-761-8889-425  
Mail: info@atg-biosynthetics.de  ·  Web: www.atg-biosynthetics.com  
Founded: 2001  ·  Employees: 6

---

**ATLAS Biolabs GmbH**

Friedrichstr. 147  ·  10117 Berlin  
Tel.: +49-30-3198966-0  ·  Fax: +49-30-3198966-19  
Mail: customer-support@atlas-biolabs.com  ·  Web: www.atlas-biolabs.com  
Founded: 2006  ·  Employees: 14

---

ATLAS Biolabs fulfills the requirements for designing and manufacturing in vitro diagnostic medical devices according to ISO 13485:2012/AC:2012. ATLAS Biolabs’ processes are subject to rigorous quality control at all stages according to the international standards of ISO 9001:2008.

ATLAS Biolabs is a leading European service provider of complex analyses in molecular genetics, including next generation sequencing, target sequence enrichment, microarray analyses and mass spectrometry supplemented by high-level statistics/bioinformatics support and RNA/DNA isolation from biological specimens. It was founded in 2006 as a spin-off of the RZPD, German Resource Center for Genomics, and the CCG, Cologne Center for Genomics. The company is located in Cologne and Berlin. ATLAS Biolabs’ services are certified by Affymetrix, Agilent, and NimbleGen. Its customers include clinicians and registered doctors as well as pharmaceutical and biotechnological companies, and academic institutions both in Germany and abroad.
bio.logis Genetic Information Management GmbH
Altenhöferallee 3 · 60438 Frankfurt
Tel.: +49-69-53084370 · Fax: +49-69-530843711
Mail: info@gim.biologisgroup.com · Web: www.gim.biologisgroup.com
Founded: 2013 · Employees: 25

bio.logis Genetic Information Management GmbH translates genetic data into medically leverageable information and makes it available to physicians and patients. To that end, it has developed a special “Genetic Information Management Suite (GIMS)” IT solution which, in the process chain required for genetic diagnostics, focuses on the “last mile” to physicians and patients by merging raw genetic data with clinically leverageable knowledge for prompt application. GIMS supports physicians both in laboratories for automatically generating such expert content, and in hospitals with specific clinical suggestions.

The diagnostic reports and medical recommendations generated with GIMS are delivered straight to the point of care via laboratory and physician information systems as well as electronic health records.

BioMath GmbH
Schnickmannstr. 4 · 18055 Rostock
Tel.: +49-381-3756610 · Fax: +49-381-37566118
Mail: central@biomath.de · Web: www.biomath.de
Founded: 1990

BioMath is a service provider for the life sciences, i.e. of mathematical/statistical and technical services for biology, plant breeding, agriculture, medicine, pharmaceutics or related fields. The company was founded in 1990.

The services offered by BioMath comprise statistical consultation, data management and software development, experimental design and statistical analysis of trials, surveys or experiments, systematic/scoping reviews and training. The company’s main fields of competence are statistics and informatics in medicine, pharmaceutics, biology and agriculture. BioMath has – after gaining practical experience in a ten-year period of mainly working in the field of medicine – additionally specialised to statistical consultations for biologists, agronomists and biotechnologists. This is based on strategic reorientation at the turn of the millennium due to an increasing economic meaning of biotechnology and biology.

BioMath is certified according to ISO 9001 and operates according to these quality standards.
Biomax Informatics AG
Robert-Koch-Str. 2 · 82152 Martinsried
Tel.: +49-89-895574-0 · Fax: +49-89-895574-825
Mail: info@biomax.com · Web: www.biomax.com
Founded: 1997 · Employees: 50

Biomax Informatics AG is a privately held corporation located in Planegg, Germany just outside Munich. Biomax provides best-in-class, client-focused knowledge management software solutions for the life sciences. Our flagship product BioXM™ allows for Integration, Management and Analysis of data and information—of any format, size and from any location—to yield valuable knowledge for business and research.

Founded in 1997 by leading pioneering bioinformaticians with specializations in systematic genome and computational analyses, Biomax was one of the original companies focused on providing computational solutions to the Life Sciences Industry. Our customers are leaders in their field representing all areas of the Life Sciences BioTech, Agro, Food, Pharma and Health.

BodyTel GmbH
Hufelandstr. 14 · 34537 Bad Wildungen
Tel.: +49-5621-96776-0 · Fax: +49-5621-96776-10
Mail: info@bodytel.com · Web: www.bodytel.com
Founded: 2007 · Employees: 20

BodyTel’s telemonitoring solution is used in remote care of patients with cardiac/renal failure, COPD, asthma, diabetes, hypertension and obesity. It consists of: various vital sensors (blood glucose, blood pressure, weight, lung function, etc.), an Android App and a Web Portal for patients and caregivers. The key element is the automatic transmission of measured vital parameters and the easy collection of therapy-relevant activities. Patients are able to allow trusted persons insight into their file, whereas in guided care situations the telemonitoring relationship is firmly implemented. The system offers an elaborate rules- and real-time alert-management.

Rules can range from easy detectable value aberrations beyond predefined limits up to complex medical evaluation standards. Standard interfaces can also forward patient data to specialized care systems. The complete BodyTel system is certified according to European medical regulations (MDD and IVD).
Changes in genetic material can cause serious diseases. CeGaT’s top priority is to identify disease-causing mutations in patients. All the steps, from patient and family consultation to examination, genetic testing, and creation of medical reports are carried out by our team of experts. The medical report provides the attending physician with a detailed diagnosis and support for further treatment decisions. In addition it provides a basis for patient and family counseling.

CeGaT has also specialized in the use of Next-Generation Sequencing since its foundation. In addition to using it as a tool in the diagnostic services CeGaT offers this technology as a service for customer-specific projects. The services include: Genome Sequencing, Targeted Sequencing (Exome and Panels: Agilent SureSelect; Amplicons), Restriction site associated DNA, Sequencing (RAD genotyping), RNA Sequencing (Transcriptome Sequencing, smallRNA Sequencing), and Metagenome Sequencing.

cellasys offers system solutions for microphysiometry. These include services as contract research, research and development and production and maintenance. Furthermore we are consultant for development of applications, data analysis and data interpretation.

The microphysiometric systems monitor different parameters directly at living cells. These parameters are extracellular acidification (pH), cellular respiration (pO2) and morphology (impedance) of the cells.

The measurement is label-free, parallel, continuous and in real-time. With our BioChip technology you can e.g. determine the efficiency of a drug outside of humans (or animals) prior to the start of the therapy.”
CENTOGENE has developed a comprehensive mutation database (CentoMD®) that is pivotal to offering high quality diagnostic reporting and medical interpretation; thoroughly interpret each patient’s sequence data. CENTOGENE is also a pivotal partner for multiple renowned industrials worldwide.

CENTOGENE is a worldwide leader in the field of genetic diagnostics for rare hereditary diseases – with the largest test portfolio worldwide. Testing samples from over 100 different countries allows CENTOGENE a unique insight into epidemiological basis of hereditary disorders, which is crucial in the medical result interpretation process. The company is strictly focusing on offering quality molecular genetic diagnostics, underlined by its multiple international accreditations (ISO, CAP, CLIA).

CENTOGENE’s in depth medical expertise is supported by the application of cutting-edge technologies including next generation sequencing, whole exome sequencing (CentoXome®), whole genome sequencing (CentoGenome®) and innovative biomarkers for selected diseases.

CENTOGENE AG
Schillingallee 68 · 18057 Rostock
Tel.: +49-381-20365-0 · Fax: +49-381-20362-219
Mail: office@centogene.com · Web: www.centogene.com
Founded: 2006 · Employees: 230

Historical development
The CHILI GmbH, based in Dossenheim near Heidelberg, develops innovative software for multimedia image management in medicine. This independent company, managed by its founders, was created as a spin-off from the German Cancer Research Center (DKFZ). The three founders are scientists and medical computer scientists, whose solutions for PACS and teleradiology have been on the market since 1997.

Strategy
CHILI grows with each challenge. The young, creative and highly motivated team in the field of medical informatics is the basis for the success of CHILI GmbH. The company’s strategy is oriented towards the development of innovative medical software and the cooperation with scientific institutions (e.g. German Cancer Research Center). This helps to ensure the transfer of the most recent research results into current software, which is oriented towards requirements of the market.

CHILI GmbH
Friedrich-Ebert-Str. 2 · 69221 Dossenheim
Tel.: +49-6221-18079-10 · Fax: +49-6221-18079-11
Mail: info@chili-radiology.com · Web: www.chili-radiology.com
Founded: 2002 · Employees: 48
Computomics is a team of world-leading experts in genomics research and bioinformatics, offering next-generation sequencing (NGS) analyses for biotech companies and scientists. Our advanced bioinformatics services provide our customers with quality sequencing and phenotyping data interpretation using state-of-the-art genomics tools and machine learning data integration methods.

Cortex Biophysik GmbH
Walter-Köhon-Str. 2d · 04356 Leipzig
Tel.: +49-341-48749-0 · Fax: +49-341-48749-50
Mail: info@cortex-medical.de · Web: www.cortex-medical.de
Founded: 1991

Extending limits
Since 1991, CORTEX is a competent partner in regard to spiroergometry systems and mobile respiratory gas analysis systems. Our solutions record and measure a person’s physical fitness and performance. Only if physical limits are known, they can be extended in an efficient and quantifiable manner. CORTEX’ systems exactly measure physical limits and help to extend them.

With the main product lines METALYZER and METAMAX CORTEX offers mobile and portable solutions for proven diagnostics in hospitals, doctor’s practices and training facilities. Our solutions are used by sport’s physicians, cardiologists, pulmonologists, occupational and rehabilitation physicians, coaches and sports scientists around the world.

The head office in Leipzig has a worldwide network of local sales and service partners on all continents. All products are CE certified and meet European standards for quality and safety. All CORTEX partners are quality controlled in sales and service.
Cunesoft GmbH is a provider of regulatory master data management software and services for all segments within the life sciences industry. Solutions include a unique connected regulatory operations- and content analysis and data extraction platform. Smart artificial intelligence algorithms create a new dimension of regulatory process automation and lead to significant time and process cost savings as well as compliance for our customers. Software provisioning is provided as Software as a Service (SaaS). The company is headquartered in Munich (Germany) with international offices.

Cunesoft GmbH
Marsstr. 4 · 80335 München
Tel.: +49-89-235-14741
Mail: info@cunesoft.com · Web: www.cunesoft.com
Founded: 2013

Image and Tracking Algorithms
• Real-Time 6DOF Position Tracking, sensor fusion
• Object recognition and segmentation, 2D/3D filters, image registration
• 3D Ultrasound reconstruction from 2D devices
• Performance optimization with multiprocessing

Hardware
• Requirements specification according to the experience of your company and practitioners
• Customized and standard solutions for cost-effectiveness and reliability

Research
• Support of medical case studies and research
• International and interdisciplinary cooperations

Curefab Technologies designs medical software and devices. We develop according to international standards and assist in EU and FDA certification.

Curefab Technologies GmbH
Landshuter Allee 12 · 80637 München
Tel.: +49-89-78797938-0 · Fax: +49-89-78797938-90
Mail: kontakt@curefab.com · Web: www.curefab.com
Founded: 2008

Data analysis Clinical research and translational informatics Clinical decision support Software

Software development
• Embedded Software from 8bit RISC to 32bit ARM
• GPGPU computing for High Performance
• Application Software for Linux/Windows
Product Development and Consulting
• Functional and Technical Conception
• Early Prototyping
• Development of hardware and software
• Observing relevant international standards, including tests and certification
• Transfer to series production, support of manufacturing
DECODON GmbH
Walther-Rathenau-Str. 49a · 17489 Greifswald  Tel.: +49-3834-5152-30 ·  Fax: +49-3834-5152-39
Mail: info@decodon.com · Web: www.decodon.com
Founded: 2000 · Employees: 5

DECODON GmbH is a bioinformatics company that develops innovative software for the modern Life Sciences. Its bioinformatics tools are helping scientists to generate knowledge from the massive amounts of data that are accumulated by recent methods in global functional genomics.

The company brings together specialists with diverse backgrounds from Molecular Biology, Computer Science and Mathematics. Software development at DECODON is driven by the needs of leading researchers in the field of functional genomics and realized by using advanced methods from various areas of Mathematics and Informatics. DECODON’s products, Delta2D, a program for fast analysis of 2D electrophoresis images, and Protecs, an information system for functional genomics studies, prove the efficiency of this approach.

Dr. Oestreich + Partner GmbH
Venloer Str. 47-53 · 50672 Köln  Tel.: +49-221-9128-710 ·  Fax: +49-221-9128-711
Mail: info@OandP-CRO.com ·  Web: www.OandP-CRO.com
Founded: 1991 · Employees: 20

We are a full-service CRO operating in Europe with certification according to ISO 9001. We offer comprehensive, complete or individual solutions for clinical studies in the pharmaceutical area (phase II to IV as well as PASS, PAES, NIS, proof of additional benefit, economy studies) for more than 20 years. We also conduct literature research, perform clinical studies and handle tasks in Regulatory Affairs for Medical Devices with the aim of CE-marking, first registration in the market and keeping your product on the market.

Our customers are:
· Pharmaceutical companies
· Manufacturer of Medical Devices
· Manufacturer of cosmetics
· Manufacturer of food products
· Institutions of healthcare

Since more than 15 years we offer our in-house EDC-System OPVERDI (FDA: CFR21 Part 11) as an internet-based user interface and database system for clinical trials. OPVERDI can be individually configurated for easy, fast and efficient data collection in clinical studies and proves to be a true alternative to paper CRF.
Dr. Vetter Medical Technology

The Dr. Vetter PC-ECG System is being developed by doctors since 1991. Our goal was to build an ecg device which is easy to use, easy to learn and easy to integrate into your daily routines.

ecSeq GmbH

ecSeq GmbH is Europe’s leading provider of hands-on bioinformatics workshops and professional, customer-oriented data analysis in the field of Next-Generation Sequencing (NGS). They help their customers to get the most out of their NGS experiments by developing tailored data analysis strategies and on-topic expert consulting. Several times a year, ecSeq GmbH organizes public workshops and conducts on-site trainings on NGS data analysis at well-known companies and academic institutes. Their bioinformatics team consists of research professionals with solid expertise in the analysis of NGS data.

Since up-to-date expert knowledge is the key to generating impactful biological insights, ecSeq GmbH established an extensive network of outstanding scientists, to assure scientific sound analyses and consultations. They offer the advantages of both, academia and industry: Fast and reliable analyses or software solutions, designed and implemented using the priceless experience of experts in the field.

---

Dr. Vetter Medizintechnik
Gablonzer Str.5 · 76185 Karlsruhe
Tel.: +49-721-55907-0 · Fax: +49-721-55907-99
Mail: info@dr-vetter.com · Web: www.dr-vetter.com
Founded: 1987

ecSeq GmbH
Brandvorwerkstr. 43 · 04275 Leipzig
Tel.: +49-151-22290-391 · Fax: +49-341-33187-962
Mail: support@ecSeq.com · Web: www.ecSeq.com
Founded: 2012
EvoCare Telemedizin GmbH
Muggenhofer Str. 136 · 90429 Nürnberg
Tel.: +49-911-32380-0
Mail: info@evocare.de · Web: www.telemedizin.de
Founded: 1995

Germany enables a new standard in Healthcare using digital Health. The method has been registered as EvoCare-Treatment. The EvoCare-treatment is the only digital treatment covered by cost bearers. This means that patients can be treated at home while the cost bearer pays for it. Clinics and centers treat patients from their telemedical EvoCare departments and earn new money this way. Patients can get treatment at home, become healthy faster, and reintegrate to work faster. Elderly can remain in the privacy of their own home for longer, sauer and healthier. EvoCare GmbH enables clinics, care providers, doctors and cost bearers the implementation. At the end evocare realize "digital" treatment for their patients as a running business.

GenXPro GmbH
Altenhöferallee 3 · 60438 Frankfurt am Main
Tel.: +49-69-9573-9710 · Fax: +49-69-9573-9706
Mail: pwinter@genxpro.de · Web: www.genxpro.de
Founded: 2005 · Employees: 15

Excellence in Genomics, Transcriptomics, Epigenetics and Bioinformatics

GenXPro provides state of the Next Generation Sequencing solutions and comprehensive data-analysis for quick and convenient access to the relevant information in your data.

Our service portfolio comprises a large spectrum of techniques for the analysis of DNA, its methylation, as well as coding and non-coding RNA. GenXPro invented "TrueQuant", a technique to avoid PCR-introduced bias, a major problem of all sequence-based quantitative data. Besides the standard NGS techniques like RNA-Seq, smallRNA-Seq, Methyl-Seq we offer "MACE" (Massive Analysis of cDNA Ends) a powerful and cost-efficient technique that implies the "TrueQuant" method for the analysis of gene expression, alternative poly-Adenylation, allele-frequencies and for genotyping even of small amounts (e.g. from liquid biopsies) and degraded RNA, such as from FFPE samples.

GenXPro's know-how and sophisticated bioinformatics for complex data is currently transferred into pipelines for precision medicine, to provide the best possible treatment in cancer.
HASOMED GmbH
Paul-Ecke-Str. 1 · 39114 Magdeburg
Tel.: +49-391-62301-12 · Fax: +49-391-62301-13
Mail: info@hasomed.de · Web: www.hasomed.de
Founded: 1991 · Employees: 85

HASOMED GmbH is an owner-managed company focusing on neurological rehabilitation. Originally established in 1991 Kronberg, the company was relocated in 1995 to Magdeburg. Dr. Peter Weber and Matthias Weber are owners and CEOs. HASOMED GmbH are a spin-off from the Department of Science of the Medical Faculty of the University Magdeburg. Thus the focus of activities during first years of establishment was on development and manufacturing of research technology.

The generative environment Magdeburgs led to an accumulation of know-how in human resources and technologies within the company. HASOMED’s capacity regarding the development of hardware, software and electronics led to products well established in the market for neurological rehabilitation.

All products of HASOMED GmbH have been developed in close interdisciplinary cooperation with medical partners, especially with rehabilitation clinics.

For 25 years, the system RehaCom has evolved and used for the rehabilitation of brain injured individuals. Nowadays RehaCom is market leader in computer-assisted cognitive rehabilitation.

---

HealthTwiSt GmbH
Lindenberger Weg 80 · 13125 Berlin
Tel.: +49-30-450-540807 · Fax: +49-30-450-540988
Mail: info@healthtwist.de · Web: www.healthtwist.de
Founded: 2003 · Employees: 3

HealthTwiSt is providing cutting-edge services for data management as well as statistical analyses.

Our framework provides you with field-tested web-based Electronic Case Report Forms (eCRF) tailored to your needs. Our eCRFs give advantages in terms of progress monitoring, data consistency, and speed of access to results. Our in-house development brought together clinicians, study nurses, statisticians, and programmers, driven by our own research needs. Data management services are available for clinical as well as basic research.

Statistical analyses are based on the principles of reproducible research. Scripts bundle all steps from raw data import, coding, filtering, applying statistics, up to presenting results in tables and highly informative figures.

Data science as provided by HealthTwiSt leads to thinking with data. It is more than ‘just’ statistics: In combination with data mining techniques it can unveil structures in research results beyond hypotheses.
I.E.M. GmbH  
Cockerillstr. 69 · 52222 Stolberg  
Tel.: +49-2402-9500-0 · Fax: +49-2402-9500-11  
Mail: info@iem.de · Web: www.iem.de  
Founded: 1993

I.E.M. is a researcher, developer and manufacturer of validated medical products and services in the field of cardiovascular screening, diagnostics and follow-up management.

As cutting-edge technologies I.E.M. has integrated the pulse wave analysis algorithm, being thereby able to capture central hemodynamic parameters by an upper-arm cuff measurement over a circadian cycle with the Mobil-O-Graph® 24h PWA Monitor.

I.E.M. for years now maintains the technology leadership in e-health telecommunication systems, allowing for remote monitoring of vital parameter data.

In addition to information on products and services I.E.M. offer matching concepts and information around the topic of hypertension, in several languages.

Its global network provides I.E.M. with know-how, information and suggestions that take direct impact on the development, product design and marketing concepts.

Complying with a broad variety of national and international certifications and registrations, I.E.M. successfully implemented its products and services on global markets.

Made in Germany since 1993.

IMGM Laboratories GmbH  
Bunsenstr. 7a · 82152 Martinsried  
Tel.: +49-89-4524667-0 · Fax: +49-89-4524667-410  
Mail: info@imgm.com · Web: www.imgm.com  
Founded: 2001 · Employees: 17

IMGM Laboratories, founded 2001, is a genomic service provider focusing on BIOMARKER DISCOVERY, METAGENOMICS, BIODISTRIBUTION and PHARMACOGENETICS. Our broad technology portfolio includes NEXT GENERATION SEQUENCING (Illumina MiSeq, NextSeq and HiSeq), MICROARRAYS (Illumina, Agilent and Affymetrix) and qPCR (TaqMan) as well as ddPCR (BioRad). Expert bioinformatics and comprehensive reporting complete our services.

Most novel methodologies encompass all sequencing steps derived from FFPE material as well as development of “enteralis-kit” in connection to MVZ Martinsried, our sister company.

IMGM holds a GLP certificate and an ISO 17025 accreditation for Sanger sequencing and gene expression analysis and SNP genotyping using both real-time PCR and microarray technologies and is certified service provider for Illumina (CSPro), Agilent and Affymetrix. Should you be interested in gene expression analysis, 16S RNA or gene panel sequencing, we are looking forward to hearing from you. For further information please visit www.IMGMM.com.
infoteam Software AG

infoteam Software AG is an established provider of software solutions and services in industry, life science and medical engineering with an international base of customers. The company employs 174 staff members in its headquarters in Bubenreuth near Erlangen and in other branches in Germany, Switzerland and China. The company is certified according to ISO 9001 and ISO 13485.

Related to medical devices infoteam provides software engineering, testing and realisation. Whether for device software, operating software, image processing or integration in higher level networks, devices in medical technology without customised software solutions are simply unimaginable. infoteam uses its process for standard-compliant software development according to IEC 62304, IEC 62366, ISO 14971 and FDA standards as CFR 21 Part 11, 510(k) etc. On this basis the company realises 3D visualisation of medical data, embedded software engineering for medical devices and platform independent software applications for mobile devices called medical apps.

Insilico Biotechnology AG

Insilico Biotechnology is a market-leading company providing predictive solutions for the Bioeconomy. An interdisciplinary team of experts offers mechanistic models, customized software, and a high performance computing platform for the simulation of living cells.

For world-leading pharma and biotech companies Insilico’s technology lowers time, risk and costs of development processes. Founded in 2001, Insilico is a privately held company based in Stuttgart, Germany. For further information, please visit www.insilico-biotechnology.com.
JPT Peptide Technologies GmbH
Volmerstr. 5 · 12489 Berlin
Tel.: +49-30-6392-5500 · Fax: +49-30-6392-5501
Mail: info@jpt.com · Web: www.jpt.com
Founded: 2004 · Employees: 60

JPT Peptide Technologies is a leading provider of innovative peptide-based services (e.g. custom peptide synthesis), and catalog products & kits (e.g. Peptide Pools and SIL Peptide Standards), as well as a partner for projects in Immunology, Proteomics and Drug Discovery.

JPT's head office and production sites are located in Berlin, Germany. All of its production and services are performed in Berlin/Germany in accordance with DIN EN ISO 9001:2015 guidelines. JPT is serving a worldwide customer base in the pharmaceutical and biotechnology industries, as well as researchers in universities, governmental and non-profit organizations.

Over the past decade, JPT has developed a portfolio of proprietary technologies and a series of unique products and services which support research efforts in proteomics, all development phases of novel vaccines or immunotherapies and peptides based drug discovery.

Kapelan Bio-Imaging GmbH
Prager Str. 60 · 04317 Leipzig
Tel.: +49-341-35599-770 · Fax: +49-341-35599-779
Mail: info@kapelanbio.com · Web: www.kapelanbio.com
Founded: 2000 · Employees: 6

Kapelan Bio-Imaging is a bio-imaging company from Leipzig, Germany. We develop and distribute software and imager for digital image analysis in research and routine. Our software LabImage provides a unique approach for all bio-imaging needs from image analysis up to automation and device controlling. LabImage provides the world only Imaging Application Pool.

In combination with the LabImageR reader series we create custom solutions for use in routine diagnostics mainly. The readers are made to work in close combination with the Labimage software. They are built to deliver a fully integrated workflow to provide a more efficient and flexible process.

The LabImage Application Pool is a set of Apps that can be loaded directly into the LabImage Software. The Labimage Application Pool is a set of Apps that can be loaded directly into Labimage.

You probably know the concept from your smartphone running iOS, android or Windows Phone or others on the market. You can select from a huge list of specific apps according to your needs.
The Lead Discovery Center (LDC) is a translational drug discovery company which takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads that address unmet medical needs.

In close collaboration with high profile partners from academia and industry, LDC is building a strong and growing portfolio of preclinical assets with exceptional medical and commercial potential.

LDC sustains a preferred partnership with the Max Planck Society and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, J&J Innovation, Merck/EMD, Qurient and Roche as well as leading academic drug discovery centers around the globe.

The LDC offers core expertise in Cellular Biology, Assay Development & Screening, Pharmacology and Medicinal Chemistry in a collaborative risk-sharing model. The LDC team consist of industry-trained experts with solid experience in project management and drug discovery.

LDC GmbH
Otto-Hahn-Str. 15 · 44227 Dortmund
Tel.: +49-231-9742-7000 · Fax: +49-231-9742-7039
Mail: info@lead-discovery.de · Web: www.lead-discovery.de
Founded: 2008 · Employees: 62

Lipotype is a spin-off company from the Kai Simons and Andrej Shevchenko labs of the world-renowned Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany. Drawing on many years of cutting edge research experience, Lipotype delivers comprehensive, absolutely quantitative lipid analysis services for clinical and biological samples on a high-throughput scale.

Lipotype offers high quality lipid analysis services for a wide range of customers and applications including biomarker identification for clinical researchers, pharma and biotech companies, functional food development for the food industry, as well as for the small-scale profiling needs of academic researchers.

Lipotype GmbH
Tatzberg 47 · 01307 Dresden
Tel.: +49-351-796-5345 · Fax: +49-351-796-5349
Mail: info@lipotype.com · Web: www.lipotype.com
Founded: 2012 · Employees: 11
LOGOPHARM GmbH
Schloßstr. 14 · 79232 March
Tel.: +49-761-203-5127 · Fax: +49-761-203-5191
Mail: info@logopharm.com · Web: www.logopharm.com
Founded: 2005 · Employees: 4

LOGOPHARM GmbH is an innovative biotech company that provides specialized services and tools for proteomic target and biomarker R&D. The company located at Freiburg (Germany) was established 2005 by a team of leading scientists and business experts. It combines proprietary proteomic technologies, long-term experience in functional membrane protein analysis and innovative drug development concepts with focus on membrane proteins and protein complexes.

Our proprietary developments include the CompleXio technology for identification of protein-protein interactions in native tissue, microproteomic analysis with ultimate sensitivity and label-free quantitative mass spectrometry. The used strategies are broadly applicable to targets and biomarkers, require very small amounts of sample and show a lower error rate than current high-throughput approaches. Based on this we offer advanced proteomic services, research consulting and implementation of technology, individually adapted to our customers' needs.

med3D GmbH
Lutherstr. 59 · 69120 Heidelberg
Tel.: +49-6221-5027-50 · Fax: +49-6221-5027-51
Mail: info@med3D.de · Web: www.med3D.de
Founded: 2000

med3D GmbH is a company focused on software development and clinical research. Very strong in 3D image processing and 3D visualization, surgical navigation and robotics. Spin-Off from Heidelberg University Hospital in 2000, located next to campus. Main product: 3D planning system for dental implantology based on computertomographic 3D image data (using data acquired with CT and Cone Beam CT). Actively involved in research for telemedicine and early warning systems for sepsis and atrial fibrillation.
MEDEORA GmbH
Hansaring 1 · 50670 Köln
Tel.: +49-221-9883-0360 · Fax: +49-221-9883-0361
Mail: info@medeora.de · Web: www.medeora.de
Founded: 2004

MEDEORA GmbH (a University Hospital of Cologne spin-off) is for more than 12 years a privately owned company, which specializes in the development of solutions for the pharmaceutical industry and medical science.

Our products include software solutions for managing biological samples and patient data, solutions for the implementation of scientific research projects and pharmaceutical studies (NIS/PASS: website solutions for physicians and patients and much more). In addition, we have a national and international network of partners in the areas of communications and marketing, market research and media (www.quomedic.com).

As an ISO 9001 2015 certified company we place great emphasis on structured and sustainable processes.

Our Biobanking Software "BioARCHIVE" is a user friendly, customizable sample management solution that supports the flow in a lab and it is ideal for small and mid-sized Biobanks in the areas of medicine and life sciences. BioARCHIVE (medicine and science) is available as Cloud version, On Site-version and as Freeware version (www.cloud-biobanking.com).

MEDEORA GmbH
Hansaring 1 · 50670 Köln
Tel.: +49-221-9883-0360 · Fax: +49-221-9883-0361
Mail: info@medeora.de · Web: www.medeora.de
Founded: 2004

The MEIERHOFER Group is a European technology company that provides solutions for managing medical and administrative processes in health care facilities. The scalable information system MCC is a leading hospital information system in Germany, Austria and Switzerland. Currently, about 80,000 users work in about 220 installations with MCC.

Starting in 1987 as a student start-up, today nearly 200 MEIERHOFER employees fill the company’s fundamental ideas with life: connecting people, medicine and IT. We place great emphasis on software suitable for daily use.

Short distances and direct contact: as a medium sized enterprise we know our customers and assist them with their projects at any time. Our offices in Munich, Leipzig, Berlin, Bern (CH) and St. Valentine (AT) ensure proximity to MCC users from Germany, Switzerland and Austria.

MEIERHOFER AG
Werner-Eckert-Str. 12 · 81829 München
Tel.: +49-89-442316-0
Mail: info@meierhofer.de · Web: www.meierhofer.de
Founded: 1987 · Employees: 200

The MEIERHOFER Group is a European technology company that provides solutions for managing medical and administrative processes in health care facilities. The scalable information system MCC is a leading hospital information system in Germany, Austria and Switzerland. Currently, about 80,000 users work in about 220 installations with MCC.

Starting in 1987 as a student start-up, today nearly 200 MEIERHOFER employees fill the company’s fundamental ideas with life: connecting people, medicine and IT. We place great emphasis on software suitable for daily use.

Short distances and direct contact: as a medium sized enterprise we know our customers and assist them with their projects at any time. Our offices in Munich, Leipzig, Berlin, Bern (CH) and St. Valentine (AT) ensure proximity to MCC users from Germany, Switzerland and Austria.
Metabolomic Discoveries GmbH
Am Mühlenberg 11 · 14476 Potsdam
Tel.: +49-331-95143881
Mail: info@metabolomicediscoveries.com · Web: www.metabolomicediscoveries.com
Founded: 2009 · Employees: 15

Metabolomic Discoveries is a research company in the field of metabolomics. The metabolomics platform allows the identification of biomarkers in diagnosis of disease, for well-being and health prevention.

The company developed a unique single blood drop at home sampling kit, which allows to analyse about 1000 metabolites in blood. The platform, named Kenkodo, provides direct to consumer tests, as well as it enables clinical studies to increase blood sampling resolution and monitoring of participants by mobile applications and wearable devices.

Metabolomic Discoveries develops biomarkers in the field of precision medicine, nutrition, exercise and aging. Here, artificial intelligence approaches such as deep learning to identify patterns and develop predictive models.

micro-biolytics GmbH
Schelztorstr. 54-56 · 73728 Esslingen
Tel.: +49-711-901-211-20 · Fax: +49-711-901-211-900
Mail: info@micro-biolytics.com · Web: www.micro-biolytics.com
Founded: 2001 · Employees: 12

Digitization of liquids is a gap which still exists in a world of digital information. Until today no valid method is available to close this gap and to provide all the benefits to industries and organizations.

This gap can be closed – today.

Micro-Biolytics has developed a new analytical method named AquaSpec™. Each liquid has a specific infrared spectrum, individual as a fingerprint.

With AquaSpec™ any liquid (e.g. blood serum or pharmaceutical drugs) is analysed at once with previously unattained reproducibility of measurements, accuracy and detection sensitivity. All compounds are detected at once and – digitized.

The information is stored in a Big Data storage for further information. The digital image of a liquid is unlimited and available at any time for further analysis.

AquaSpec™ is:
• Easy (no special skills or environment required, no sample preparation)
• Fast (result in less than 3 min.)
• Reliable (each AquaSpec™ device provides for the same liquid, the same result)
• Best in class price performance ratio

AquaSpec™ can solve many problems in many application areas.
They enable pharmaceutical and biotech companies to accelerate early drug testing and allow research organizations to gain new insights into cancer, multiple sclerosis, chronic infections, and other diseases.

microDimensions develops and distributes software for microscopic image processing and analysis. Their solutions and services can be tailored to individual requirements and seamlessly integrated into digital pathology workflows.

microDimensions’ cutting-edge products Voloom®, Slidematch™, Outspace™, and Zoom are the world’s fastest tools for convenient and accurate 3D histology reconstruction, whole slide image alignment, stereology, and digital pathology viewing.

MicroDiscovery develops and produces software and hardware solutions for mHealth, in-vitro-diagnostics and biomedical research enabling personalized medicine.

Our innovative analysis system, mo:Test, a smartphone based user friendly reader for lateral flow test evaluation makes diagnostics mobile. Quick high quality readout, quantification and reliable documentation are guaranteed in all applications. Intelligent integration of a smartphone makes the system fully autonomous and reduces maintenance effort.

MicroDiscovery has a strong track record in creating analysis systems for molecular data, image analysis, classification and medical device control. This includes the design and realization of dedicated algorithms in the fields of Genomics, Proteomics and Metabolomics. Solutions can be developed and documented as required for CE certification and FDA compliance (21 CRF part 11, IEC 62304). Complementary bioinformatics and biostatistics services support your study planning, biomarker validation, data processing, data integration and data management.
Molecular Health is a data and analytics precision medicine company based in Heidelberg, Germany with affiliates in Boston and in The Woodlands, USA. As a medical device company we strictly follow the associated regulations. We capture, integrate, and analyze the most recent scientific and medical knowledge using our comprehensive biomedical data warehouse (Dataome).

We exploit Dataome to match individual patient genetic profiles with state-of-the-art biomedical knowledge to identify safe and effective therapies.

Our goal is to empower physicians with evidence base to make better treatment decisions for their cancer patients. Molecular Health provides a fast and scalable platform (Dataome) that turns the latest biomedical information into clinically actionable knowledge to improve individual patient outcomes.

NEXUS AG
Irmastr. 1 · 78166 Donaueschingen
Tel.: +49-771-22960-0 · Fax: +49-771-22960-999
Mail: info@nexus-ag.de · Web: www.nexus-ag.de

NEXUS is one of the leading European software companies for the healthcare industry with more than 2,500 customers in 19 countries.

NEXUS offers Patient Management, Billing, Electronic Medical Record, CPOE, Medication, Charting, Medication, Nursing, Picture Management, Operation Theatre, PDMS-ICU and many other medical modules. The software is designed for ease of use, without requiring menus, to guide the user with one click to the required information.

NEXUS provides a complete and integrated software suite to healthcare institutions. Highlights: in addition to the hospital information system (HIS) NEXUS is offering premium medical diagnostic (DIS) modules – like solutions for radiology, endoscopy or cardiology – which can also be used independently of NEXUS/HIS.

For the specific requirements of acute, mental health, rehabilitation and home care facilities, NEXUS offers customer focused solutions by providing individual process support and specific modules and functions. In Germany, Austria and Switzerland, more than 60% of all mental health institutions use NEXUS.
nova motum® Services & Consulting GmbH
Goerzallee 299 · 14195 Berlin
Tel.: +49-30-915 757-20 · Fax: +49-30-915 757-21
Mail: info@novamotum.net · Web: www.novamotum.net
Founded: 2013

Know-how and experience
nova motum® offers more than 18 years experience in the development and design of Mobile Connectivity software. We know how to expand your business strategy with the help of Mobile Connectivity, based on solutions for iOS, Android, as well as OS X and Linux, clients and servers alike. Our customer base includes Vodafone Global, Phonak, Medisana, and Gigaset, amongst others.

Network
nova motum® has access to the eHealthCare markets as an active member of bvitg – German Association of Health IT Vendors and of SPECTARIS, section medical technology; of COCIR in Brussels, electromedical and HealthCare IT industries. also of ZVEI, German Electrical and Electronic Manu-

Our competent team of biologists, physicists and biochemists makes sure to constantly achieve the best possible results for all kinds of projects – reliably, fast and cost-effi-
cient. The OakLabs headquarters are located in Hennigsdorf near Berlin.

The portfolio includes:
• carefree packages for gene expression analysis
• comprehensive data analyses and diagnostics
• development of custom software solutions

OakLabs GmbH
Neuendorfstr. 16b · 16761 Hennigsdorf
Tel.: +49-3302-2265-479 · Fax: +49-3302-209-2705
Mail: info@oak-labs.com · Web: www.oak-labs.com
Founded: 2011 · Employees: 12

Our competent team of biologists, physicists and biochemists makes sure to constantly achieve the best possible results for all kinds of projects – reliably, fast and cost-effi-
cient. The OakLabs headquarters are located in Hennigsdorf near Berlin.

The portfolio includes:
• carefree packages for gene expression analysis
• comprehensive data analyses and diagnostics
• development of custom software solutions
OmicScouts GmbH
St.-Valentin-Str. 5 · 85356 Freising
Tel.: +49-8161-714-265 · Fax: +49-8161-714-264
Mail: info@omicScouts.com · Web: www.omicScouts.com
Founded: 2014 · Employees: 7

OmicScouts is a proteomics company providing innovative proteomics and integrated bioinformatics solutions for key issues in drug and biomarker discovery. Founded in 2014 as spin-off of the TU München, the company supports drug discovery, disease and systems biology and (pre-)clinical research with a broad portfolio of advanced mass-spectrometry-based technologies.

OmicScouts’ chemical proteomics technologies alongside the licensed Cellular Thermal Shift Assay (CETSA) technology reveal cellular drug targets and selectivity profiles in an unbiased and comprehensive manner. Other technologies enable the proteome-wide profiling of posttranslational modifications and signalling mechanisms for drug mode-of-action analyses or biomarker discovery studies.

Above all, OPASCA’s focus always remains with human beings: while efficient patient management and practical assistance systems specifically for radiation therapy facilities purposefully support and release professional staff, various components of the universal platform enable patient-customized care during the entire treatment cycle for the purpose of increasing the patient’s well-being.

OPASCA GmbH
Julius-Hatry-Str. 1 · 68163 Mannheim
Tel.: +49-621-150282-70 · Fax: +49-621-150282-71
Mail: kontakt@opasca.com · Web: www.opasca.com
Founded: 2010 · Employees: 30

OPASCA – business activity

OPASCA realizes a smart interconnection and workflow optimization for the medical sector on the basis of a diverse and flexible platform concept in close collaboration with our users in public, church-related or privately operated hospitals and practices. At present, our business operations focus on radiation therapy facilities.

Our highly modular concept combines essential functional modules for room surveillance in radiation therapy facilities into one integrated complete solution. Technological highlight is the worldwide unique personal safety system that prevents unintentional radiation collisions without the need for any marking.
PharmaInformatic was founded in 2004 and provides software and databases to improve drug discovery and development. The company is based in Emden, Germany.

Since twelve years we develop large & comprehensive databases on ADME/Tox properties of drugs & compounds (Absorption, Distribution, Metabolism, Excretion, Toxicology, Bioavailability, Protein binding, etc).

By using Artificial Intelligence we create software (Expert Systems) which predicts above properties solely by compound structure. Pharmaceutical companies use the software IMPACT-F to evaluate drug-uptake in humans prior to clinical trials.

Our research replaces animal tests: Drug uptake is tested in animals such as dogs, rats, monkeys or mice to estimate uptake in humans. But human and animal drug uptake is often different. The expert system IMPACT-F evaluates oral drug uptake significantly more reliably than animal tests. Pharmaceutical companies use the technology to optimize the development of future drugs.

For customers testimonials & further info, see: http://pharmainformatic.com

PolyQuant GmbH offers a wide range of products, services and supporting bioinformatics solutions for quantitative proteomics.

The proprietary QconCAT technology enables absolute quantification of proteins using proteotypic peptides which are isotopically labeled, and as such function as internal standards in LC-MS analysis. QconCATs are overall beneficial: they facilitate simple handling from sample preparation to data analysis, and they enable highly reproducible throughputs (multiplexing to 1000’s of samples/data points scalable). Additionally, inherent features of the polypeptide are stability, quantification accuracy, and general robustness. Therefore, QconCATs are valuable research tools for biomarker discovery and validation.

Building on our in-depth expertise, we offer:
- customized QconCATs as internal standards for absolute protein quantification
- calibration kits “RePLICal” and “QCAL” for LC and MS instrument standardization
- entire assay development (full fee-for-services)
- technical support for the implementation of targeted proteomics assays.
Preventicus GmbH
Tatzendpromenade 2 · 07745 Jena
Tel.: +49-3641-559845-0 · Fax: +49-3641-559845-9
Mail: info@preventicus.com · Web: www.preventicus.com
Founded: 2014 · Employees: 8

Preventicus offers eHealth solutions for preventing lifestyle-related diseases like stroke and burnout. The USPs of Preventicus include unique algorithms based on biosignal analytics and high-level clinical evidence that enable risk screening via smartphones. Personalized prevention measures are derived from the individual’s health profile, while their effectiveness is monitored and users networked to health providers.

Lifestyle-related diseases like heart attack, burnout and stroke are usually not detected until serious symptoms become manifest. This encumbers effective prevention and generates enormous costs. Smartphones and smartwatches represent the ideal screening instrument. However, currently, there are hardly clinical, evidence-based applications for early detection, preventive care and risk assessment available.

Protagen AG
Otto-Hahn-Str. 15 · 44227 Dortmund
Tel.: +49-231-9742-6300 · Fax: +49-231-9742-6301
Mail: bd@protagen.com · Web: www.protagen.com
Founded: 1997 · Employees: 40

Protagen AG improves Personalized Patient Care

We are an ISO 13485 certified diagnostic company, passionate about validation and development of novel biomarkers for better diagnostic (Dx) and companion diagnostic (CDx). Our SeroTag® technology enables differential diagnosis and patient stratification for Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) and others.

Our first CE marked tests for SSc were launched in Q2/2016 and further tests in SLE and RA will follow. Protagen is also developing diagnostics products that predict a patient’s response to treatments to some of the best selling drugs in the world. Together with our Pharma and Biotech partners,

Preventicus GmbH offers eHealth solutions for preventing lifestyle-related diseases like stroke and burnout. The USPs of Preventicus include unique algorithms based on biosignal analytics and high-level clinical evidence that enable risk screening via smartphones. Personalized prevention measures are derived from the individual’s health profile, while their effectiveness is monitored and users networked to health providers.

Lifestyle-related diseases like heart attack, burnout and stroke are usually not detected until serious symptoms become manifest. This encumbers effective prevention and generates enormous costs. Smartphones and smartwatches represent the ideal screening instrument. However, currently, there are hardly clinical, evidence-based applications for early detection, preventive care and risk assessment available.

Protagen AG has developed the NavigAID concept. The first product, NavigAID SLE, separates and defines patient subgroups in SLE, overcoming patient heterogeneity and enabling new approaches for successful drug development.

At Protagen, we are dedicated to the development of novel diagnostic tests that aid successful therapeutic development and better treatment strategies for autoimmune diseases.
Proteome Factory AG
Magnusstr. 11 · 12489 Berlin
Tel.: +49-30-206162-65 · Fax: +49-30-206162-67
Mail: service@proteomefactory.com · Web: www.proteome-factory.com
Founded: 2000

Proteome Factory (PFA) is a contract research organization providing protein analysis, quality control, proteomics, metabolomics and high resolution mass spectrometric services to all fields of biological, biomedical and chemical research and recombinant/therapeutic protein production.

PFA provides a comprehensive array of chromatographic, electrophoretic (including 2DE analysis), protein chemical and mass spectrometric techniques to match customer’s analysis requirements with tailored solutions for their projects. Therefore, PFA is a preferred partner of customers from pharmaceutical, biotech and research institutes for R&D projects especially in the field of proteomics and biomarker discovery, quantification of proteins in products, drugs or biological samples, full amino acid sequencing of proteins (e.g. monoclonal antibodies) and characterization of (recombinant) proteins, biosimilars and biobetters.

Apart from contract research PFA offers high quality fee-for-service analytical and mass spectrometric services which can be delivered also as express services.

QIAGEN
Qiagen Str. 1 · 40724 Hilden
Tel.: +49-2103-29-0 · Fax: +49-2103-29-22000
Mail: pr@qiagen.com · Web: www.qiagen.com
Founded: 1984 · Employees: 4,600

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows.

QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
QuoMedic GmbH
Am Mediapark Hansaring 1 · 50670 Köln
Tel.: +49-221-988-303-70 · Fax: +49-221-988-303-61
Mail: info@quomedic.de · Web: info@www.quomedic.com
Founded: 2013

QuoMedic is the result of 12 years experience of Medeora GmbH, a technology company with focus on software solutions to support studies and research projects (EDC solution, website for patients and physicians). Our combination of expertise and experience in supporting patient- and site-based activities across multiple countries makes us an invaluable resource that strengthens every recruitment effort.

Partnership means trust. As an agency that relies on successful cooperation with partners, we rely on our affiliate Medeora in all technical matters and our American partner BBK Worldwide in the field of adaptive patient recruitment, a specialist with more than 30 years of innovative recruitment success in 72 countries and more than 50 languages.

We compose fresh solutions to achieve your goals through: TCN-System (data input and management solutions), My Clinical Study Buddy (Appointment reminders, Visit overviews, EC-approved study materials), Protocoll Pal (Pre-screening tool, Regulatory-approved documents), RSG Card (Ready.Set.Go. Card Global Patient Reimbursement Program).

Ribocon GmbH
Fahrenheitstr. 1 · 28359 Bremen
Tel.: +49-421-2487-053 · Fax: +49-421-2208-150
Mail: contact@ribocon.com · Web: www.ribocon.com
Founded: 2005 · Employees: 8

Ribocon is a bioinformatics company committed to the computational aspects of molecular identification and community profiling of microorganisms with a focus on (i) high-quality DNA sequence reference databases and data sets (marker genes such as the ribosomal RNA, as well as genomes) and (ii) bioinformatics tools and services for off-the-shelf data processing based on standardized processes.

Ribocon’s mission is to transform and extend academic state-of-the-art resources and solutions to finally comply with the requirements of e.g. highly regulated user environments such as in pharmaceutical industry.
samedi GmbH
Hessische Str. 11 · 10115 Berlin
Tel.: +49-30-21230707-0
Mail: info@samedi.de · Web: www.samedi.de
Founded: 2008 · Employees: 20

The samedi GmbH offers an interdisciplinary, web-based software for collaboration of healthcare providers. It is based on a common workflow scheduling and patient coordination fulfilling the highest security requirements. Hospitals, clinics and other medical providers can use the online platform www.samedi.de to manage their workflows and resource planning without any additional hardware and by that achieve an optimized utilisation. The integrated online booking system offers the possibility to book appointments via internet and without making any telephone calls.

The relationship between doctor and patient becomes easier, more cost-effective, more time-saving and more service-oriented at the same time. The administrative effort is reduced and on the other hand the patient care gets optimised.

Hereby samedi® supports doctors and hospitals to fulfill their requirements concerning quality management. The system is financed without advertising, by a monthly subscription of the customers. samedi® is a completely independent, privately funded provider of technological services.

Scopis GmbH
Heinrich-Heine-Platz 10 · 10179 Berlin
Tel.: +49-30-20169-380 · Fax: +49-30-20169-3820
Mail: info@scopis.com · Web: www.scopis.com
Founded: 2010

Scopis® GmbH, based in Berlin (Germany), develops and manufactures surgical planning and navigation systems for Neuro, Spine, ENT and maxillofacial surgery. Scopis Target Guide Surgery (TGS®) is a unique "next-generation" solution for navigated endoscopic surgery that offers surgeons highly advanced image guidance and visualization capabilities.

Scopis TGS® is provided by the Scopis Hybrid Navigation® system that is the first clinical navigation platform that offers electromagnetic, optical and simultaneous hybrid tracking technology in a single integrated control unit. Scopis operates in over 50 countries.
Siemens Healthineers is one of the world’s largest suppliers of technology to the healthcare industry and a leader in medical imaging, laboratory diagnostics and healthcare IT. All supported by a comprehensive portfolio of clinical consulting, training, and services available across the globe and tailored to customers’ needs.

In fiscal 2015, Siemens Healthineers had around 44,000 employees worldwide and posted revenue worth 12.9 billion euros, and profits of more than 2.1 billion euros. Further information is available on the Internet at http://www.healthcare.siemens.com

Sonormed GmbH
Neuer Kamp 30 · 20357 Hamburg
Tel.: +49-40-609451195
Mail: service@tinnitracks.com · Web: www.tinnitracks.com
Founded: 2012

Sonormed, founded in 2012, is based in Hamburg, Germany. An interdisciplinary team of sound engineers, computer scientists, psychologists and neurobiologists is constantly working on further developing and distributing the medical products Tinnitracks and Tinimatch. The company has won numerous innovation and entrepreneur awards and was honored, e.g., by the German Federal Ministry of Economics and Technology. In 2015 Tinnitracks could win the Great Prize at the SXSW Accelerator competition in the category “Digital Health Life Science”.

Sonormed started Tinnitracks as a web application but soon advanced the service to smartphone apps on iOS and Android. In September 2015, Tinnitracks became the first mobile therapy app in Germany to be reimbursed by a statutory health insurance company. To broaden access to Tinnitracks, Sonormed is now targeting the US market. With its technological infrastructure and direct market access, Sonormed is ideally positioned to promote change in digital patient care and to benefit from the convergence of consumer electronics and healthcare in audiology.
StarSEQ GmbH
Johann-Joachim-Becher-Weg 30a · 55099 Mainz
Tel.: +49-6131-39232-87
Mail: info@starseq.com · Web: www.starseq.com
Founded: 2008 · Employees: 8

StarSEQ is a research and service oriented enterprise.

Although founded only in 2008, StarSEQ unites a considerable measure of technical competence. Starting 1 January, 2014, StarSEQ GmbH has taken over the operative business of GENterprise GmbH. As a result of the takeover of additional fields of business, StarSEQ GmbH has broadened its services to encompass molecular biology, biotechnology and diagnostics. The founders of GENterprise have decades of experience in nucleic acid analysis. Their experience ranges from the first gene technological applications of the mid-1970s to the decoding and characterization of genes with the most modern high throughput technology in the framework of genome projects.

Systasy Bioscience GmbH
Adams-Lehmann-Str. 56 · 80797 München
Tel.: +49-151-51263366
Mail: info@systasy.de · Web: www.systasy.com
Founded: 2012 · Employees: 10

Systasy, a growing start-up company founded 2012 in Munich, provides cost-effective and highly innovative solutions to address critical and unmet needs of the pharmaceutical industry. Systasy’s products and services are ranging from the analysis of cellular target activities and specificities up to the simultaneous analysis of multiple pathway in living cells, based on their proprietary splitSENSOR and EXTassay technologies.

Systasy takes advantage of their EXTassay technology to deliver profile analyses for a multitude of simultaneously occurring cellular events to customers. Thus, Systasy’s services and products are designed to match customers’ needs in the early phases of drug discovery and personalized medicine.
Tembit Software GmbH advises the pharmaceutical industry as well as hospitals on the use of biobanks, their interfaces with clinical information systems, incorporating biobanks into the existing infrastructure as well as on the integration of the necessary process steps into day-to-day work taking into account data protection, technology and organizational aspects. In cooperation with our customers, we develop individual procedures, analyze and optimize existing processes and implement programmatic requirements in a timely and validated manner.

Our focus is on the following questions:
• In an international environment, how can human specimens, collected in small to large projects, be stored securely and in keeping with data protection requirements?
• What measures are to be taken to ensure effective international data protection for data and patients?
• How can clinical parameters be used to find human and or *omics-specimens efficiently?
• How can the required re-validation effort pursuant to 21 CFR part 11 be handled economically?
• We provide convenient answers.

Tembit Software GmbH
Am Borsigturm 42 · 13507 Berlin
Tel.: +49-30-60988-3111 · Fax: +49-30-60988-3122
Mail: info@tembit.de · Web: www.tembit.de

Transinsight is the leading provider for bioinformatics solutions. The ESI® Technology is a semantic search technology for enterprises. It is highly flexible and modular, which allows us to create the right solution for your unique needs. This technology operates according to principles which go far beyond common search strategies. It combines knowledge based semantic technologies with exceptionally intuitive navigation. The well known semantic search engine GoPubMed.com shows all principles online for free.

In acknowledgement of the technologies developed by the company, Transinsight has repeatedly been honoured with international awards i.e. the reddot design award best of the best 2009 and the German Industry Prize 2010.

Transinsight GmbH
Tatzberg 47–51 · 01307 Dresden
Tel.: +49-351-79657-80
Mail: info@transinsight.com · Web: www.transinsight.com
Founded: 2005
A key feature of JiveX products is an open system structure that allows for seamless integration in existing IT architectures, regardless of the manufacturer. This is made possible by consistently implementing internationally recognized IHE standards. The use of standards creates transparency and serves as a prerequisite for an expandable, forward-looking IT infrastructure that offers users the development flexibility they need.

VISUS is one of the leading providers of process-oriented solutions for imaging and diagnostic management. The JiveX product family covers the full range of imaging and diagnostic data communication, from PACSs for radiology clinics to hospital solutions spanning multiple departments and sites. Thanks to their use of internationally recognized standards, VISUS solutions – all of which are developed in Germany – can be readily integrated into existing systems.

Vitaphone has been a leading company in the area of telemedicine since its foundation in 1999. The company offers e-health solutions in four main segments. The first segment is monitoring, which involves monitoring vital data for chronic conditions with the help of medical devices and supporting software. The second one constitutes telemedical services provided by our specialized callcenter and its qualified medical personnel. The third segment is providing vital data monitoring, support and reporting in the context of clinical trials. Finally, vitaphone is involved in consulting work regarding the entire telemedicine process.

All of these different areas of work are made possible through vitaphone’s telemedical infrastructure (software and devices) at the base level. The main goals of vitaphone are to connect regional and national healthcare stakeholders and develop new innovative healthcare models that improve the patient’s quality of life and can furthermore be effective tools to face challenges posed by the ageing population and decreasing amounts of medical professionals.
Center for Human Genetics and Laboratory Diagnostics

The Center for Human Genetics and Laboratory Diagnostics in Martinsried is specialized in advanced laboratory testing in genetics, clinical chemistry and immunology (in particular: HLA testing). The laboratory is accredited according to DIN EN ISO/IEC 17025 and ISO 15189. The institution’s clinical consultation focuses on pediatric genetics, infertility and inherited diseases. Among the applied technologies are: PID, NIPT (Prenatalis®), Next Generation and Sanger Sequencing as well as Array technologies, Blotting, FACS, FISH, HPLC, pyrosequencing, real-time PCR and tandem mass spectrometry. Since 2016 the portfolio includes the molecular genetic analysis of the human microbiome (enteralis).
About us
Health – Made in Germany is an initiative of Germany’s Federal Ministry for Economic Affairs and Energy. Our mission is to strengthen the competitiveness of the German healthcare industry and actively promote the internationalization of the sector. Particular emphasis here is on the support of small and medium enterprises.

Health – Made in Germany is conducted by Germany Trade & Invest, the economic development agency of the Federal Republic of Germany.

Germany Trade & Invest
Health – Made in Germany
Friedrichstraße 60
10117 Berlin
Germany
T +49 (0)30 200 099-0
F +49 (0)30 200 099-111
office@gta.com
www.gta.com
www.health-made-in-germany.com